4-吗啉基苯基异硫氰酸酯 | 51317-66-9

• 物质功能分类: 化学试剂 - 有机试剂 - 硫氰酸盐/异硫氰酸酯
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 中文名称: 4-吗啉基苯基异硫氰酸酯
• 中文别名: 4-(4-异硫氰苯)吗啡林
• 英文名称: 4-(4-isothiocyanato-phenyl)morpholine
• 英文别名: 4-(4-isothiocyanatophenyl)morpholine；4-morpholinylphenyl isothiocyanate；4-morpholinophenyl isothiocyanate；4-(4-isothiocyanato-phenyl)-morpholine；4-morpholin-4-yl-phenyl isothiocyanate；4-(4-isothiocyanate-phenyl)-morpholine
• CAS: 51317-66-9
• 化学式: C₁₁H₁₂N₂OS
• mdl: MFCD00047409
• 分子量: 220.295
• InChiKey: AXUXRZZYZBZQAR-UHFFFAOYSA-N

物化性质

• 熔点：
  84 °C
• 沸点：
  394.4±37.0 °C(Predicted)
• 密度：
  1.20±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.363
• 拓扑面积：
  56.9
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 危险品标志：
  Xn
• 安全说明：
  S26,S36/37/39
• 危险类别码：
  R20/21/22,R36/37/38
• 海关编码：
  2934999090
• WGK Germany：
  3
• 储存条件：
  室温

SDS

Name:	4-Morpholinophenyl isothiocyanate Material Safety Data Sheet
Synonym:	None Known
CAS:	51317-66-9

Section 1 - Chemical Product MSDS Name:4-Morpholinophenyl isothiocyanate Material Safety Data Sheet
Synonym:None Known

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
51317-66-9	4-Morpholinophenyl isothiocyanate	97+	unlisted

Hazard Symbols: XN
Risk Phrases: 20/21/22 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Harmful by inhalation, in contact with skin and if swallowed.
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation. May cause chemical conjunctivitis.
Skin:
Causes skin irritation. Harmful if absorbed through the skin.
Ingestion:
Harmful if swallowed. May cause gastrointestinal irritation with nausea, vomiting and diarrhea.
Inhalation:
Harmful if inhaled. Causes respiratory tract irritation.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or appropriate foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Clean up spills immediately, observing precautions in the Protective Equipment section. Sweep up or absorb material, then place into a suitable clean, dry, closed container for disposal. Avoid generating dusty conditions. Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Minimize dust generation and accumulation. Avoid contact with eyes, skin, and clothing. Keep container tightly closed. Avoid ingestion and inhalation. Use with adequate ventilation. Wash clothing before reuse.
Storage:
Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 51317-66-9: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
A respiratory protection program that meets OSHA's 29 CFR 1910.134 and ANSI Z88.2 requirements or European Standard EN 149 must be followed whenever workplace conditions warrant respirator use.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: yellow
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: 48-50 deg C @ 3mmHg
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C11H12ON2S
Molecular Weight: 220.295

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable at room temperature in closed containers under normal storage and handling conditions.
Conditions to Avoid:
None reported.
Incompatibilities with Other Materials:
Acids, amines, bases, reducing agents, oxidizing agents.
Hazardous Decomposition Products:
Carbon monoxide, oxides of nitrogen, oxides of sulfur, carbon dioxide.
Hazardous Polymerization: Will not occur.

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 51317-66-9 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
4-Morpholinophenyl isothiocyanate - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: TOXIC LIQUID, ORGANIC, N.O.S.
Hazard Class: 6.1
UN Number: 2810
Packing Group: III
IMO
Shipping Name: TOXIC LIQUID, ORGANIC, N.O.S.
Hazard Class: 6.1
UN Number: 2810
Packing Group: III
RID/ADR
Shipping Name: TOXIC LIQUID, ORGANIC, N.O.S.
Hazard Class: 6.1
UN Number: 2810
Packing group: III

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XN
Risk Phrases:
R 20/21/22 Harmful by inhalation, in contact with
skin and if swallowed.
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 23 Do not inhale gas/fumes/vapour/spray.
S 24/25 Avoid contact with skin and eyes.
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
WGK (Water Danger/Protection)
CAS# 51317-66-9: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 51317-66-9 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 51317-66-9 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-吗啉基苯基异硫氰酸酯 在 hydrazine hydrate 作用下， 以 乙醇 为溶剂， 反应 4.0h， 生成 4-[(4-morpholinyl)phenyl]thiosemicarbazide
  参考文献：
  名称：

  一系列基于氨基硫脲的新型抗炎药通过抑制环氧合酶发挥作用

  摘要：

  为了鉴定有效的抗炎剂，制备并入二芳基醚框架 ( 2a-2l ) 的新型氨基硫脲 (TSC) 并筛选其对环氧合酶 (COX) 的体外抑制作用。4-[4-(Piperidin-1-ylsulfonyl)phenyl]-1-[4-(4-cyanophenoxy)benzylidene]thiosemicarbazide ( 2c ) 是该系列中最有效和选择性最强的 COX-1 抑制剂，IC 50值1.89 ± 0.04 µM。另一方面，4-[4-(哌啶-1-基磺酰基)苯基]-1-[4-(4-硝基苯氧基)亚苄基]氨基硫脲 ( 2b ) 被鉴定为非选择性 COX 抑制剂 (COX-1 IC 50  = 13.44 ± 0.65 µM，COX-2 IC 50 = 12.60 ± 0.78 µM）。基于分子对接研究，二芳基醚和 TSC 基团是与 COX 活性位点中关键氨基酸残基相互作用的关键部分。根据M

  DOI：

  10.1002/ardp.202200136
• 作为产物：
  描述：

  4-(4-硝基苯基)吗啉 在 FeO(OH)/C 、 一水合肼 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 反应 5.0h， 生成 4-吗啉基苯基异硫氰酸酯
  参考文献：
  名称：

  发现苯并[d]恶唑衍生物作为有效的I型FLT3-ITD抑制剂。

  摘要：

  Fms样酪氨酸激酶3（FLT3）被认为是治疗急性髓性白血病（AML）的潜在药物靶标，因为它在AML患者（尤其是具有FLT3-ITD突变的患者）中高表达异常。从受打击的化合物（IC50：针对FLT3-ITD的500 nM）开始，基于苯并[d]恶唑-2-胺骨架设计并合成了一系列化合物，以发现新的有效FLT3-ITD抑制剂。在药物化学工作中，使用灵活的分子对接来提供设计依据并研究目标化合物的结合模式。通过基于酶和细胞活性的混合SAR探索，鉴定出化合物T24具有有效的FLT3-ITD抑制（IC50：0.41 nM）和抗增殖（IC50：0.037μM，针对MV4-11细胞）活性。

  DOI：

  10.1016/j.bioorg.2019.103248

文献信息

• Synthesis and Biological Evaluation of Arylthiourea Derivatives with Antitubercular Activity
  作者：Rusong Luo、Tuomo Laitinen、Liyan Teng、Tapio Nevalainen、Maija Lahtela-Kakkonen、Baofu Zheng、Honghai Wang、Antti Poso、Xuelian Zhang

  DOI：10.2174/1570180811310070012

  日期：2013.6.1

  Tuberculosis (TB) is a contagious disease caused by Mycobacterium tuberculosis (M. tuberculosis), and remains one of the most life-threatening plagues for public health in the world. The emergence of drug resistant strains of TB and co-infection with HIV has further complicated TB treatment. Here, the synthesis and characterizaton of a series of compounds were described, and these were followed by evaluating for their antibacterial activity against M. tuberculosis. Several novel arylthiourea derivatives exhibited excellent activity (lowest MIC=0.09 μg/ml) against M. tuberculosis including drug resistant strains of M. tuberculosis. The results suggest that these compounds are promising candidates for new anti-TB agent development.

  结核病（TB）是一种由结核分枝杆菌（M. tuberculosis）引起的传染性疾病，仍然是全球公共卫生的最致命威胁之一。耐药TB菌株的出现以及与HIV的共同感染进一步复杂化了结核病的治疗。本文描述了一系列化合物的合成与表征，随后对其抗菌活性进行了评估，特别是针对结核分枝杆菌。几种新型芳基硫脲衍生物显示出卓越的活性（最低MIC=0.09 μg/ml），能有效对抗包括耐药菌株在内的结核分枝杆菌。这些结果表明，这些化合物是有希望的新型抗结核药物开发候选者。
• Synthesis and Evaluation of α-Thymidine Analogues as Novel Antimalarials
  作者：Huaqing Cui、Juana Carrero-Lérida、Ana P. G. Silva、Jean L. Whittingham、James A. Brannigan、Luis M. Ruiz-Pérez、Kevin D. Read、Keith S. Wilson、Dolores González-Pacanowska、Ian H. Gilbert

  DOI：10.1021/jm301328h

  日期：2012.12.27

  Plasmodium falciparum thymidylate kinase (PfTMPK) is a key enzyme in pyrimidine nucleotide biosynthesis. 3-Trifluoromethyl-4-chloro-phenyl-urea-α-thymidine has been reported as an inhibitor of Mycobacterium tuberculosis TMPK (MtTMPK). Starting from this point, we designed, synthesized and evaluated a number of thymidine analogues as antimalarials. Both 5′-urea-α- and β-thymidine derivatives were moderate

  恶性疟原虫胸苷酸激酶 ( Pf TMPK) 是嘧啶核苷酸生物合成的关键酶。3-Trifluoromethyl-4-chloro-phenyl-urea-α-thymidine 已被报道为结核分枝杆菌TMPK ( Mt TMPK)的抑制剂。从这一点出发，我们设计、合成并评估了许多作为抗疟药的胸苷类似物。5'-尿素-α-和β-胸苷衍生物都是Pf TMPK 的中度抑制剂，并且还显示出对寄生虫生长的中度抑制。几种酶-抑制剂复合物的结构为改进抑制剂设计提供了基础。然而，我们发现某些 5'-尿素-α-胸苷类似物具有抗疟活性，其中PfTMPK 不是主要的作用方式。该系列的优化产生了具有有效抗疟活性的化合物（EC 50 = 28 nM；CC 50 = 29 μM）。
• [EN] DERIVATIVES OF PHENYL (THIO) UREA DEOXYTHYMIDINE AND USE THEREOF AS ANTIMALARIALS<br/>[FR] DÉRIVÉS DE PHÉNYL(THIO)URÉEDÉSOXYTHYMIDINE ET LEUR UTILISATION COMME ANTIPALUDIQUES
  申请人：UNIV DUNDEE

  公开号：WO2013014445A1

  公开（公告）日：2013-01-31

  Deoxythymidine derivatives according to formula (I) are disclosed. wherein: X may be O or S; and R1, R2, R3, R4 and R5 may each be independently selected from H, halo, C1-C6 alkyl, C1-C6 haloalkyl, nitro, phenyl, heteroaryl, substituted heteroaryl wherein the substituents may be C1-C6 alkyl or C1-C6 haloalkyl, benzyl, -CH2OAr, -OR6 and six-membered ring heterocyclic groups containing 1 or more O and/or N heteroatoms wherein any N heteroatom may be C1-C6 alkyl-substituted; and R6 may be selected from C1-C6 alkyl, phenyl, six-membered ring heterocyclic groups containing at least one O heteroatom, benzyl and substituted benzyl wherein the substituents may be halo, C1-C6 alkyl or C1-C6 alkoxy; R7 may be H or C1-C6 alkyl; and the stereochemistry of the bond depicted as 〰 is either α or β. Such derivatives have shown good inhibitory activity against malaria-causing parasites, e.g. Plasmodium falciparum, but have shown low levels of toxicity to human cells.

  根据公式（I），披露了脱氧胸苷衍生物。其中：X可以是O或S；R1、R2、R3、R4和R5可以分别独立地选择自H、卤素、C1-C6烷基、C1-C6卤代烷基、硝基、苯基、杂环芳基、取代的杂环芳基，其中取代基可以是C1-C6烷基或C1-C6卤代烷基、苄基、-CH2OAr、-OR6和含有1个或多个O和/或N杂原子的六元环杂环基团，其中任何N杂原子可以是C1-C6烷基取代的；R6可以选择自C1-C6烷基、苯基、含有至少一个O杂原子的六元环杂环基团、苄基和取代的苄基，其中取代基可以是卤素、C1-C6烷基或C1-C6烷氧基；R7可以是H或C1-C6烷基；而所示键的立体化学为α或β。这些衍生物已显示出对引起疟疾的寄生虫，如疟原虫（Plasmodium falciparum），具有良好的抑制活性，但对人类细胞的毒性水平较低。
• Synthesis, activity, and pharmacokinetic properties of a series of conformationally-restricted thiourea analogs as novel hepatitis C virus inhibitors
  作者：Iou-Jiun Kang、Li-Wen Wang、Teng-Kuang Yeh、Chung-Chi Lee、Yen-Chun Lee、Sheng-Ju Hsu、Yen-Shian Wu、Jing-Chyi Wang、Yu-Sheng Chao、Andrew Yueh、Jyh-Haur Chern

  DOI：10.1016/j.bmc.2010.07.002

  日期：2010.9

  evaluated for their anti-HCV activity. Herein we report the synthesis, structure–activity relationships (SARs), and pharmacokinetic properties of this new class of thiourea compounds that showed potent inhibitory activities against HCV in the cell-based subgenomic HCV replicon assay. Among compounds tested, the fluorene compound 4b was found to possess the most potent activity (EC50 = 0.3 μM), lower cytotoxicity

  设计，合成并评估了一系列新颖的构象限制的硫脲类似物的抗HCV活性。在这里，我们报告了这种新型的硫脲化合物的合成，结构-活性关系（SAR）和药代动力学特性，这些硫脲化合物在基于细胞的亚基因组HCV复制子测定中显示出对HCV的有效抑制活性。 与相应的芴酮化合物4c相比，在所测试的化合物中，发现芴化合物4b具有最强的活性（EC 50  = 0.3μM），较低的细胞毒性（CC 50 > 50μM）和显着更好的药代动力学特性。
• Discovery and Optimization of Selective Inhibitors of Meprin α (Part II)
  作者：Chao Wang、Juan Diez、Hajeung Park、Christoph Becker-Pauly、Gregg B. Fields、Timothy P. Spicer、Louis D. Scampavia、Dmitriy Minond、Thomas D. Bannister

  DOI：10.3390/ph14030197

  日期：——

  Meprin α is a zinc metalloproteinase (metzincin) that has been implicated in multiple diseases, including fibrosis and cancers. It has proven difficult to find small molecules that are capable of selectively inhibiting meprin a, or its close relative meprin b, over numerous other metzincins which, if inhibited, would elicit unwanted effects. We recently identified possible molecular starting points

  Meprinα是一种锌金属蛋白酶（metzincin），与多种疾病有关，包括纤维化和癌症。事实证明，很难找到能够选择性抑制美普林a或其近亲美普林b的小分子，而不是许多其他二甲双胍，如果被抑制，将引起不希望的作用。我们最近确定了通过HTS的作用而对meprin a特异性抑制的可能的分子起点（请参阅上篇论文的第一部分）。在第二部分中，我们在此报告了为优化效能和选择性所做的进一步努力。我们希望异羟肟酸甲铁蛋白α抑制剂探针将有助于确定小分子甲铁蛋白a抑制作用的治疗潜力，并刺激锌金属蛋白酶抑制领域的进一步药物开发工作。